- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02975518
Tracking Endothelial Cells in Arterial Injury
We plan to track the migratory behaviour of culture-expanded enothelial outgrowth cells in the context of vascular injury sustained during elective coronary angiography.
We will use Flouro-deoxyglucose-labelling and PET-CT to track the endothelial cells.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The radial artery is commonly injured following trans-radial cardiac catheterisation and this injury can be demonstrated as a reduction in endothelial function as measured by flow-mediated dilatation which recovers with time (13-15). Thus the radial artery is useful as a model of mechanical arterial injury as radial artery trauma is common and endothelial function can be followed longitudinally with a non-invasive test.
Endothelial progenitor cells localise to sites of arterial injury in animal models both in vitro and in vivo and accelerate re-endothelialisation as well as attenuating neointimal hyperplasia (16-18), This has however not been demonstrated in man.
Our research group, in collaboration with the Scottish Blood Transfusion Service (SNBTS) have developed a good manufacturing practice (GMP)-compliant process for manufacturing an endothelial progenitor cell (EPC) product (SNBTS will manufacture the final product administered to patients). We have also demonstrated in vitro that we can label these cells with the radioisotope 18 F-fluorodeoxyglucose (18F-FDG) and that activity can be detected in as few as 200 cells using a hybrid positron emission and computed tomography (PET-CT) scanner (Biograph mCT Siemens Medical Systems, Erlangen, Germany). We will therefore be able to track the fate of these cells in vivo. The major potential advantage of imaging in this way is that only 18F-FDG associated with EPCs will be delivered to the patient, removing the issue of background attenuation due to "free" circulating 18F-FDG. A similar technique has previously been employed in vivo to track homing of unselected autologous bone marrow cells to infarcted myocardium(19). Following intracoronary delivery using this technique, the authors were able to detect 1.3% - 2.6% of 18F-FDG-labelled cells in the infarcted myocardium. Demonstrating that EPCs are able to home to and integrate at sites of vascular injury in man is a critical step in understanding the role of EPCs in vascular repair
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Midlothian
-
Edinburgh, Midlothian, United Kingdom, EH74DL
- University of Edinburgh
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Undergoing coronary angiography for known or suspected ischaemic heart disease
Exclusion Criteria:
- Previous coronary artery bypass surgery.
- Planned angiography via the femoral artery as a sole arterial access route
- Anaemia <10g/L
- Severe valvular heart disease
- Acute myocardial infarction within previous three months
- Cardiac failure (Killip class ≥II).
- Insulin dependent diabetes mellitus
- Hepatic failure (Childs-Pugh grades B or C).
- Renal failure (estimated glomerular filtration rate <25 mL/min).
- Intercurrent illness including patients with a systemic inflammatory disorder or underlying malignancy.
- Women of child-bearing age not ensuring reliable methods of contraception.
- Inability to provide informed consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Intra-venous infusion of Flourodeoxyglucose
As a control for radio labelled cells, Flourodeoxyglucose will be administered intra-venously at an activity equal to that injected with the labelled endothelial cells.
|
Radio labelled endothelial outgrowth cells will be administered to patients undergoing elective coronary angiography and stenting.
They will be administered intra-venously and intra-arterially (right radial artery) in separate arms.
Migratory behaviour of these cells will be defined using PET CT.
Intra-venous and intra-arterial injection of free radio tracer will serve as a control comparator arms.
|
Active Comparator: Intra-Arterial infusion of Flourodeoxyglucose
As a control for radio labelled cells, Flourodeoxyglucose will be administered intra-arterially at an activity equal to that injected with the labelled endothelial cells.
|
Radio labelled endothelial outgrowth cells will be administered to patients undergoing elective coronary angiography and stenting.
They will be administered intra-venously and intra-arterially (right radial artery) in separate arms.
Migratory behaviour of these cells will be defined using PET CT.
Intra-venous and intra-arterial injection of free radio tracer will serve as a control comparator arms.
|
Experimental: Intra-venous injection of radio-labelled endothelial cells
Endothelial cells labelled with flourodeoxyglucose will be injected intra-venously with their distribution tracked using PET CT.
|
Radio labelled endothelial outgrowth cells will be administered to patients undergoing elective coronary angiography and stenting.
They will be administered intra-venously and intra-arterially (right radial artery) in separate arms.
Migratory behaviour of these cells will be defined using PET CT.
Intra-venous and intra-arterial injection of free radio tracer will serve as a control comparator arms.
|
Experimental: Intra-Arterial injection of radio-labelled endothelial cells
Endothelial cells labelled with flourodeoxyglucose will be injected intra-arterially with their distribution tracked using PET CT.
|
Radio labelled endothelial outgrowth cells will be administered to patients undergoing elective coronary angiography and stenting.
They will be administered intra-venously and intra-arterially (right radial artery) in separate arms.
Migratory behaviour of these cells will be defined using PET CT.
Intra-venous and intra-arterial injection of free radio tracer will serve as a control comparator arms.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Standard uptake value
Time Frame: 0-4 hours
|
Standard-uptake values of injured sections of artery will be compared to remote uninjured artery
|
0-4 hours
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Protocol v 3
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
China National Center for Cardiovascular DiseasesRecruitingLeft Main Coronary Artery DiseaseChina
Clinical Trials on Administration of radio labelled endothelial outgrowth cells
-
University of EdinburghRoyal College of Surgeons of Edinburgh; Translational Medicine Research CollaborationCompletedHealthy VolunteerUnited Kingdom
-
University of EdinburghBritish Heart Foundation; Translational Medicine Research CollaborationCompleted
-
Zhejiang UniversityCompletedIdiopathic Pulmonary Arterial HypertensionChina
-
Zhejiang UniversityCompletedIdiopathic Pulmonary Arterial HypertensionChina
-
Zhejiang UniversityUnknownIdiopathic Pulmonary Arterial HypertensionChina
-
Tufts UniversityMassachusetts General HospitalWithdrawn
-
University Hospitals, LeicesterBritish Heart FoundationCompletedMyocardial Infarct | Bone Marrow CellsUnited Kingdom
-
University Hospital, MontpellierAssistance Publique - Hôpitaux de Paris; University Hospital, Clermont-Ferrand and other collaboratorsTerminatedParkinson Disease | Brain Trauma | Probable Alzheimer Disease | Neurological Disease Without Cognitive Degradation | Acute HydrocephalyFrance
-
AlloCure Inc.St Mark's Hospital Foundation; Intermountain Health Care, Inc.CompletedKidney Tubular Necrosis, AcuteUnited States
-
Assistance Publique - Hôpitaux de ParisSuspended